扶正化瘀胶囊联合派罗欣对丙型肝炎肝纤维化的干预作用研究  

Effects of Fuzheng Huayu Capsules combined with peginterferon on liver fibrosis in hepatitis C patients

作　　者：黄利华[1] 胡敏涛[1] 姚上志[1] 张波[1] 蒲云川[1] 裴豪[1] 

机构地区：[1]无锡市第五人民医院传染科,江苏无锡214000

出　　处：《中国中医基础医学杂志》2014年第5期653-655,共3页JOURNAL OF BASIC CHINESE MEDICINE

基　　金：无锡市科技局社会发展基金资助项目(CSE01009)

摘　　要：目的:观察扶正化瘀胶囊对丙型肝炎患者肝纤维化的改善作用。方法:入组65例丙型肝炎肝纤维化患者,按随机数字表法分为治疗组和对照组,对照组使用派罗欣治疗,治疗组加用扶正化瘀胶囊治疗48周,比较2组之间以及治疗前后肝功能、血清肝纤维化4项指标和肝脾B超检查的结果。结果:治疗48周后,治疗组总有效率明显高于对照组,治疗组肝功能指标ALT、AST、TBIL比治疗前有明显下降,ALB有明显升高,血清纤维化4项指标PCⅢ、Ⅳ-C、LN和HA均有明显改善,B超显示门静脉直径、脾脏厚度和脾静脉内径均有明显缩小。而对照组ALT、AST、TBIL比治疗前有明显下降,但ALB没有明显升高,血清纤维化4项指标中也仅有PCⅢ和HA获得改善,B超显示只有门静脉直径缩小。更为重要的是,治疗48周后治疗组与对照组比较,TBIL有明显下降,ALB有明显升高,肝纤维化4项指标均有明显改善。结论:丙型肝炎肝纤维化患者派罗欣联合扶正化瘀胶囊治疗比单用派罗欣有更为明显的改善肝脏功能和肝纤维化的作用。Objective： To observe the ameliorating effects of Fuzheng Huayu Capsules on liver fibrosis in hepatitis C patients. Methods： A total of 65 patients were assigned randomly to two groups： the treatment group, which received peginterferon plus Fuzheng Huayu Capsules for 48 weeks; and the control group, which received peginterferon for 48 weeks. Liver function, the index of liver fibrosis and results of liver and spleen B-mode ultrasound examination were compared either between two groups or before and after treatment. Results ： The total effective rate of treatment group was obviously higher than that of control group 48 weeks after treatment. Liver function index of ALT, AST, TBIL was significantly lower, ALB is higher and the index of liver fibrosis PC Ⅲ, IV-C ,LN and HA was markedly ameliorated, portal vein diameter, the thickness of the spleen and splenic venous diameter narrowed down after 48 weeks treatment compared to that before treatment in treatment group. By contrast, although ALT, AST, TBIL in control group was significantly lower compared to that before treatment, ALB was not increased, and only PC Ⅲ and HA of index of liver fibrosis was ameliorated. Additionally, ultrasound examination showed that only portal vein diameter got smaller. Notably, TBIL was downregulated, ALB was increased and four indexes of liver fibrosis were markedly ameliorated in treatment group 48 weeks after treatment compared with that in control group. Conclusions： Fuzheng Huayu Capsules combined with peginterferon significantly improved liver function and ameliorated liver fibrosis markedly compared with peginterferon treament alone in patients with HCV-associated liver fibrosis.

关 键 词：扶正化瘀胶囊 派罗欣 丙型肝炎 肝纤维化 

分 类 号：R512.33[医药卫生—内科学]